RHÖN‐KLINIKUM AG, a prominent healthcare provider in Germany, convened its 36th Annual General Meeting today. The shareholders’ assembly was conducted virtually.
Shareholders of the company demonstrated their confidence in both the Management Board and the Supervisory Board by endorsing all items on the agenda by a majority vote. In line with the joint proposal put forth by the Management Board and the Supervisory Board, the retained profit for the 2023 financial year, totaling approximately EUR 22.3 million, will be carried forward to a new account.
During his address, Chairman of the Board Prof. Dr. Tobias Kaltenbach elaborated on the company’s successful trajectory. “RHÖN-KLINIKUM AG continues to exhibit robust economic progress. This achievement is a testament to the dedicated and ongoing efforts of all employees, positioning us well for the forthcoming hospital reform. The resounding support expressed through today’s voting outcomes underscores the confidence bestowed upon us by our shareholders.”
Supervisory Board Changes
At the Annual General Meeting, three new members were appointed to the Supervisory Board.
Joachim Gemmel (52), CEO of Asklepios Kliniken GmbH & Co. KGaA, assumes the role, succeeding Kai Hankeln, who resigned from his mandate and departed from the company’s Supervisory Board effective February 13, 2024.
Additionally, PD Dr. Sara Sheikhzadeh (47), Chief Medical Officer of Asklepios Kliniken GmbH & Co. KGaA, and Dr. Dagmar Federwisch (55), Regional Managing Director of Asklepios North Hesse and NRW, were elected to the Supervisory Board. Both already serve as members of the supervisory board of the University Hospital Gießen and Marburg GmbH (UKGM). They replace Irmtraut Gürkan and Christine Reißner.
